Johnson & Johnson heads into earnings after steep December declines. Investors should focus on results in its pharma and medical devices segments.
from rss_headline http://bit.ly/2U2M2xP
via IFTTT
from rss_headline http://bit.ly/2U2M2xP
via IFTTT
Kommentare
Kommentar veröffentlichen